Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
RegulatoryapprovedREDEMPLOPositive
AI Analysis
Summary
Arrowhead Pharmaceuticals announced that REDEMPLO (plozasiran) received marketing authorization from the European Union for treating triglycerides in adults with Familial Chylomicronemia Syndrome. This regulatory approval represents a significant milestone for the company's rare disease program.
Outcome Details
Marketing Authorization received in the European Union
Importance:8/10
Sentiment:
0.90
regulatory approvalEuropean Unionmarketing authorizationrare diseasecardiovascular
Related Companies
Read the original article
Published by yahoo_finance on June 22, 2026 4:33 PM